Skip to content
Screener

Pacific Biosciences of California PACB Business Segments — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Bicara Therapeutics logo
BCAXReportable Segment — R&D
$47.5M+38.4%
YSS
YSSReportable Segment — R&D
$5.29M+20.2%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$357.46M-5.6%
Enterprise value$356.64M-4.8%
P/S2.2×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total revenue$39,007$39,766$76,185$76,919
Less:
Cost of revenue26,36925,08250,70663,606
Research and development23,02222,52942,63051,582
Sales and marketing18,49219,51634,27039,592
General and administrative14,90116,65930,27636,751
Impairment charges15,000
Settlement charges15,400

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's business segments — R&D?
Pacific Biosciences of California (PACB) reported business segments — R&D of $23.02M in Q2 2026.
How has Pacific Biosciences of California's business segments — R&D changed year-over-year?
Pacific Biosciences of California's business segments — R&D increased by 2.2% year-over-year, from $22.53M to $23.02M.
What is the long-term trend for Pacific Biosciences of California's business segments — R&D?
Over 3 years (2022 to 2025), Pacific Biosciences of California's business segments — R&D has grown at a -20.4% compound annual growth rate (CAGR), from $193M to $97.31M.
What does business segments — R&D mean?
These are the expenditures dedicated to the innovation, design, and improvement of the company's genetic sequencing platforms and software. For a biotechnology firm, this metric is critical for assessing the long-term competitive advantage and the pipeline of future product enhancements.

Ask your AI about Pacific Biosciences of California's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude